
Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients
Focusing on the unmet medical needs of patients with rare disorders and their families
Our Company
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Latest News
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol
Read MoreZynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
Read MoreZynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
Read More